Results 191 to 200 of about 259,973 (292)

Clinical Benefit of PD-1/PD-L1 Inhibitors as Standard First-Line Treatment in Low PD-L1-Expressing Advanced Solid Tumors: A Systematic Review and Meta-Analysis. [PDF]

MedComm (2020)
Wu P, Gu X, Li D, Zi X, Shang D, Liu J, Ma R, Peng J, Zhang G, Che Y, Zeng Q, Zhao B, Sun N, Zhang C, He J.   +14 more
europepmc   +1 more source

Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer

Advanced Science, EarlyView.
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen, Dingru Li, Yingna Liao, Zehua Wang, Chunbin Zhu, Zifeng Zhang, Liquan Jin, Yueyue Chen, Jiaoshun Chen, Junyi Xu, Miaoyan Wei, Rong Tang, Xianjun Yu, Si Shi   +13 more
wiley   +1 more source

Lactylation stabilizes PD-L1 to promote tumor immune evasion and cell growth. [PDF]

Cell Death Dis
Liang L, Zong Y, Huang J, Chen Y, Xu N, Yan P, Song H, Wu M.   +7 more
europepmc   +1 more source

Cryoablation Activates the cGAS–STING‐CXCL10 Axis in Macrophages to Enhance Anti‐Tumor Immunity in NSCLC

Advanced Science, EarlyView.
Tumor dsDNA released by cryoablation is taken up by macrophages, activating the cGAS‐STING signaling pathway. This leads to an expansion of the CXCL10+ macrophage pool and increased secretion of CXCL10, which in turn recruits CXCR3+ T cells from draining lymph nodes into the tumor microenvironment to exert anti‐tumor effects.
Xinxin Zhi, Zhengcao Xing, Libo Luo, Jiale Wang, Xinyu Liu, Jia Yu, Jizhong Yin, Bin Chen, Yiwei Liu, Hui Sun, Guanghui Gao, Lei Wang, Xiaoxia Chen, Fei Li, Hu Ma, Lin Wang, Shuo Yang, Shengxiang Ren   +17 more
wiley   +1 more source

Best Practice PD-L1 Staining and Interpretation in Gastric Cancer Using PD-L1 IHC PharmDx 22C3 and PD-L1 IHC PharmDx 28-8 Assays, with Reference to Common Issues and Solutions. [PDF]

Biomedicines
Ahn S, Hwang I, Kim Y, Lee S, Cho Y, Kang SY, Kim DG, Lee J, Kim KM.   +8 more
europepmc   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

Telomere damage enhances immunogenicity of neuroblastoma and accelerates response to anti-PD-L1 treatment. [PDF]

Oncoimmunology
Höppner S, Werr L, Szilagyi B, Bartenhagen C, Hellmann AM, Rosswog C, Linden E, Primke G, Kahlert Y, Ibruli N, Hemstedt N, Lorenz W, Brägelmann J, Hölzel M, Fischer M.   +14 more
europepmc   +1 more source

PD-L1 Peptide Vaccine [PDF]

, 2020
openaire   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

Advanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun, Qihong Li, Bixi Wang, Gang Wang, Ying Xue, Yibing Liang, Chenhe Hu, Zhenyu Wang, Xiaoge Gao, Haiheng Xu, Jun Song, Hailong Li, Liantao Li, Xiaoxiao Liu, Patrick Ming‐Kuen Tang, Qing Zhang   +15 more
wiley   +1 more source

PD-L1 and BAP1 as Prognostic Biomarkers in Malignant Pleural Mesothelioma. [PDF]

Cells
Gajić M, Ćeriman Krstić V, Samardžić N, Soldatović I, Glumac S, Jovanović M, Savić M, Stjepanović M, Popević S, Stević R, Čolić N, Lukić K, Milenković V, Milivojević I, Radovanović IS, Jovanović D.   +15 more
europepmc   +1 more source